Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Pattern Baldness Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending

NCT04502901
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
KX0826, Placebo
Drug · Other
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 21, 2026, 2:55 PM EDT
Active, not recruiting Phase 2 Interventional

Safety and Efficacy of VDPHL01 in Males and Females With AGA

NCT06527365
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
San Diego, California • New Albany, Indiana • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss

NCT01451099
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
6
States / cities
Atlanta, Georgia • Chevy Chase, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 21, 2026, 2:55 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss

NCT06926023
View directory record Official record
Conditions
Female Pattern Baldness
Interventions
1550nm non-ablative fractional laser, 1927 thulium fractional laser
Device
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

NCT05218642
View directory record Official record
Conditions
Alopecia, Male Pattern Hair Loss
Interventions
KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, Matching placebo to KX-826
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Fountain Valley, California • Hialeah, Florida • Hialeah Gardens, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

NCT00151515
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
minoxidil
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
15 Years to 49 Years · Male only
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Vallejo, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)

NCT01451073
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
6
States / cities
Atlanta, Georgia • Chevy Chase, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Androgenetic Alopecia in Females, 9 Beam

NCT00981461
View directory record Official record
Conditions
Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
Interventions
HairMax LaserComb, Control Device
Device
Lead sponsor
Lexington International, LLC
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Miami, Florida • Palm Beach, Florida • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 21, 2026, 2:55 PM EDT
Withdrawn Phase 2 Interventional

Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

NCT03852992
View directory record Official record
Conditions
Male Pattern Hair Loss, Androgenetic Alopecia, Male Pattern Baldness
Interventions
Post-Laser Minoxidil 2%, At-Home Minoxidil 5%, Laser, Post-laser 5mg minoxidil, Post-laser 10mg minoxidil, Post-laser 20mg minoxidil
Drug · Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

NCT01451138
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
4
States / cities
Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 21, 2026, 2:55 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO

NCT02528552
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
LH80 PRO, Sham Device
Device
Lead sponsor
Theradome, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Newnan, Georgia • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 21, 2026, 2:55 PM EDT
Recruiting Phase 2Phase 3 Interventional

Phase 2/3 Efficacy and Safety of PP405 in Adult Males

NCT07819435
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
PP405 0.05% Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
Pelage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Hot Springs, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 2:55 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Efficacy and Safety of VDPHL01 in Males With AGA

NCT06724614
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01, Placebo
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

NCT04913519
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
San Diego, California • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)

NCT01451047
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

NCT02275351
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Topical SM04554 solution, Topical vehicle solution
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Encinitas, California • San Diego, California • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Androgenetic Alopecia in Males

NCT00947505
View directory record Official record
Conditions
Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
Interventions
HairMax LaserComb 2009, 7 Beam, HairMax LaserComb
Device
Lead sponsor
Lexington International, LLC
Industry
Eligibility
25 Years to 60 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Palm Beach, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

NCT04984707
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
KX0826, Placebo
Drug · Other
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Not applicable Interventional Results available

STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

NCT02503852
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Puregraft System, Celution System, Kerastem Therapy, Liposuction
Device · Procedure
Lead sponsor
Kerastem Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Highland Park, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)

NCT01451190
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
9
States / cities
Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss

NCT01451021
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 21, 2026, 2:55 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of VDPHL01 in Males With AGA

NCT06972264
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01, Placebo
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Androgenetic Alopecia in Males and Females

NCT01437163
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System
Device
Lead sponsor
Apira Science, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Hoboken, New Jersey • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 21, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males

NCT02067260
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
X5 HairLaser, X5 Hair Laser Sham Device
Device
Lead sponsor
Spencer Forrest, Inc.
Industry
Eligibility
20 Years to 60 Years · Male only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
3
States / cities
Hot Springs, Arkansas • St. Petersburg, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Oct 21, 2026, 2:55 PM EDT